Skip to main content

Table 1 Parturient demographics and baseline characteristics of the phenylephrine, norepinephrine and control group

From: Effects of continuous infusion of phenylephrine vs. norepinephrine on parturients and fetuses under LiDCOrapid monitoring: a randomized, double-blind, placebo-controlled study

Variables

Control group (n = 78)

Phenylephrine group (n = 71)

Norepinephrine group (n = 74)

F value

P value

Age, years

34.04 (4.80)

33.34 (3.77)

33.70 (4.26)

0.4904

0.6130

Weight, kg

77.77 (12.28)

75.36 (8.43)

76.09 (11.41)

0.9642

0.3829

Height, cm

162.41 (5.72)

161.70 4.27 (4.27)

161.77 (5.46)

0.4253

0.6541

BMI, kg/m2

29.49 (4.52)

28.79 (2.59)

29.06 (3.92)

0.6635

0.5161

Baseline CO, L/min

8.42 (2.46)

7.87 (2.58)

8.43 (2.53)

1.182

0.3087

Baseline SVR, dyn s m2/ cm5

968.37 (344.23)

968.37 (269.26)

971.17 (340.18)

0.045

0.9561

Baseline SV, ml

95.83 (25.14)

91.26 (26.87)

93.85 (24.46)

0.6079

0.5454

Baseline SBP, mmHg

120.19 (11.72)

117.14 (9.66)

120.64 (12.38)

2.054

0.1306

Baseline DBP, mmHg

68.44 (13.04)

66.49 (9.79)

69.54 (11.98)

1.245

0.2901

Baseline MAP, mmHg

81.28 (15.81)

78.68 (11.31)

81.59 (18.59)

0.7657

0.4662

Baseline Heart rate, beats/min

87.38 (12.81)

87.41 (11.57)

91.16 (10.54)

2.797

0.0631

  1. BMI Body Mass Index, Data are expressed as mean (SD); SD Standard deviation. *0.25 μg/kg/min phenylephrine vs. control group, P < 0.05; #0.05 μg/kg/min norepinephrine vs. control group, P < 0.05; †0.25 μg/kg/min phenylephrine vs. 0.05 μg/kg/min norepinephrine group, P < 0.05 based on ANOVA